Valnei Canutti
medical professionalMale0.0Global Dominance: 0.00%
Valnei Canutti is a hematologist and the Chief Scientific Officer of Pint Pharma, where he emphasizes the importance of innovative therapies in treating hematological disorders. He highlighted the unique pharmacokinetic properties of BESREMi®, an innovative pegylated interferon approved for the treatment of Polycythemia Vera in Brazil.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Valnei Canutti, hematologist and Chief Scientific Officer of Pint Pharma, highlighted that BESREMi® is an innovative interferon with unique pharmacokinetic properties.
Pint Pharma Anuncia la Aprobación de BESREMi® (ropeginterferón alfa-2b) por parte de ANVISA para el Tratamiento de la Policitemia VeraEl Nacional·
Venezuela· 2025-03-21
Venezuela· 2025-03-21
